Search

Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

INCB-9471

INCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.

MBT-0312

MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.

KOS-2187

KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease

Nicaraven

Talactoferrin alfa

Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. … It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.

DDP-225

DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.

Zunsemetinib

Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

Isatoribine

Isatoribine is a selective agonist of TLR7.